+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

All Ages
MALE
ID02207894

Success of Immune Tolerance Induction Using Personalized Factor VIII Concentrate Selection to Eliminate Inhibitors in Males with Haemophilia A

Led by Haemophilia Centre Rhine Main · Updated on 2026-04-21

300

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the success of immune tolerance induction ITI in 300 male patients with haemophilia A who have developed inhibitors against factor VIII FVIII. These inhibitors complicate haemophilia treatment, and the study aims to improve management by using individualized selection of FVIII concentrates, preferably high-dose. The research also investigates how in vitro tests like thrombin generation assays, epitope mapping, and immunogenotyping relate to ITI success and inhibitor characteristics. Patients will be treated with ITI based on individualized FVIII concentrate selection and may include high-dose regimens. The study includes a pre-ITI phase to assess treatment strategies before ITI starts, including the use of bypassing agents and prophylaxis. There is a sub-study for patients who fail FVIII stand-alone ITI or require immunosuppressive agents combined with FVIII. Optional laboratory sub-studies analyze patient plasma samples to study inhibitor behavior and genetic risk factors. Participants will be monitored through regular data collection on inhibitor levels, FVIII recovery, and half-life over one year. The primary outcome measures focus on ITI efficacy defined by inhibitor titer, FVIII recovery, and half-life. Secondary outcomes will also be evaluated. Plasma samples will be tested for various laboratory markers, and treatment regimens, including immunosuppressive therapies, will be documented. The study began in 2006 and continues to follow patients for comprehensive data on ITI outcomes.

CONDITIONS

Brief Title

A Survey on the Success of Inhibitor Elimination Using Individualized Concentrate Selection and Controlled ITI

Research Team

C

Carmen Escuriola Ettingshausen, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here